(Alliance News) - AstraZeneca PLC on Tuesday said phase-three testing of its replacement efzimfotase alfa enzyme on patients affected by hypophosphatasia yielded positive safety and efficacy results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results